lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
An expanded genetic code is an artificially modified genetic code in which one or more specific codons have been re-allocated to encode an amino acid that is not among the 22 common naturally-encoded proteinogenic amino acids. The key prerequisites to expand the genetic code are:
Kuwait had been a part of the Ottoman Empire's province of Basra, something that Iraq claimed made Kuwait rightful Iraqi territory. Kuwait's ruling dynasty, the al-Sabah family, had concluded a protectorate agreement in 1899 that assigned responsibility for Kuwait's foreign affairs to the United Kingdom. The UK drew the border between Kuwait and Iraq in 1922, making Iraq almost entirely landlocked. Kuwait rejected Iraqi attempts to secure further provisions in the region. Iraq also accused Kuwait of exceeding its OPEC quotas for oil production. In order for the cartel to maintain its desired price of $18 per barrel, discipline was required. The United Arab Emirates and Kuwait were consistently overproducing; the latter at least in part to repair losses caused by Iranian attacks in the Iran–Iraq War and to pay for the losses of an economic scandal. The result was a slump in the oil price – as low as $10 per barrel ($63/m3) – with a resulting loss of $7 billion a year to Iraq, equal to its 1989 balance of payments deficit. Resulting revenues struggled to support the government's basic costs, let alone repair Iraq's damaged infrastructure. Jordan and Iraq both looked for more discipline, with little success. The Iraqi government described it as a form of economic warfare, which it claimed was aggravated by Kuwait slant-drilling across the border into Iraq's Rumaila oil field.
=== Pharmacodynamics === Both THC and CBN activate the CB1 (Ki = 211.2 nM) and CB2 (Ki = 126.4 nM) receptors. Each compound acts as a low affinity partial agonist at CB1 receptors with THC demonstrating 5x–10× greater affinity to the CB1 receptor. Like THC, CBN has a higher selectivity for CB2 receptors which are located throughout the central and peripheral nervous system, but are primarily associated with immune function. CB2 receptors are known to be located on immune cells throughout the body, including macrophages, T cells, and B cells. These immune cells have been shown to decrease production of immune-related chemical signals (e.g., cytokines) or undergo apoptosis as a consequence of CB2 agonism by CBN. In cell culture, CBN demonstrates antimicrobial effects, particularly in instances of antibiotic-resistant bacteria. CBN has also been reported to act as an ANKTM1 channel agonist at high concentrations (>20nM). While some phytocannabinoids have been shown to interact with nociceptive and immune-related signaling via transient receptor potential channels (e.g., TRPV1 and TRPM8), there is currently limited evidence to suggest that CBN acts in this way. In preclinical rodent studies, CBN, anandamide and other CB1 agonists have demonstrated inhibitory effects on GI motility, reversible via CB1R blockade (i.e., antagonism). In considering the efficacy of cannabis-based products, there remains controversy surrounding a concept termed “the entourage effect”.
Dysphoric milk ejection reflex (D-MER) is a condition in which breastfeeding women develop negative emotions that begin just before the milk letdown reflex and last less than a few minutes. It may recur with every letdown, including unexpected letdowns when the baby is not feeding. It presents as an emotional reaction but may also produce physical feelings such as nausea. It is different from postpartum depression and other known psychological conditions. A 2019 study reported a prevalence rate of 9.1%. As of 2021, very little research has been done, and many health care providers and lactation practitioners remain barely able to recognize the syndrome. An October 2021 review of literature published to that date suggested that the lack of up-to-date information "makes it necessary to educate mothers because educated mothers are usually better at handling postpartum situations if they are prepared in advance." There is as yet no medication to treat the symptoms although women have reported that they have found it of benefit to learn that they are not alone and that the symptoms were not "just in their head".
Sources: en.wikipedia.org
=== Biosynthesis and catabolism === The precursor to asparagine is oxaloacetate, which a transaminase enzyme converts to aspartate. The enzyme transfers the amino group from glutamate to oxaloacetate producing α-ketoglutarate and aspartate. The enzyme asparagine synthetase produces asparagine, AMP, glutamate, and pyrophosphate from aspartate, glutamine, and ATP. Asparagine synthetase uses ATP to activate aspartate, forming β-aspartyl-AMP. Glutamine donates an ammonium group, which reacts with β-aspartyl-AMP to form asparagine and free AMP.
In addition, Kuwait had been producing oil above treaty limits established by OPEC. By the eve of the Iraqi invasion, Kuwait had set production quotas to almost 1.9 million barrels per day (300,000 m3/d), which coincided with a sharp worldwide drop in the price of oil. By the summer of 1990, Kuwaiti overproduction had become a serious point of contention with Iraq. Some analysts have speculated that one of Saddam Hussein's main motivations in invading Kuwait was to punish the ruling al-Sabah family in Kuwait for not stopping its policy of overproduction, as well as his reasoning behind the destruction of said wells. It is also hypothesized that Iraq decided to destroy the oil fields to achieve a military advantage, believing the intense smoke plumes serving as smoke screens created by the burning oil wells would inhibit Coalition offensive airstrikes, foil allied precision guided weapons and spy satellites, and could screen Iraq's military movements. Furthermore, it is thought that Iraq's military leaders may have regarded the heat, smoke, and debris from hundreds of burning oil wells as presenting a formidable area denial obstacle to Coalition forces. The onset of the oil well destruction supports this military dimension to the sabotage of the wells; for example, during the early stage of the Coalition air campaign, the number of oil wells afire was relatively small but the number increased dramatically in late February with the arrival of the ground war.
== Epidemiology == Between 0.1% and 0.8% of people are affected. The disease is most common in Northern European countries, and per observations in the UK, is least frequently seen in people of Afro-Caribbean descent. Although the ratio of male to female disease is reportedly 3:1, many rheumatologists believe the number of women with AS is underdiagnosed, as most women tend to experience milder cases of the disease. The majority of people with AS, including 95 per cent of people of European descent with the disease, express the HLA-B27 antigen and high levels of immunoglobulin A (IgA) in the blood. In 2007, a team of researchers discovered two genes that may contribute to the cause of AS: ARTS-1 and IL23R. Together with HLA-B27, these two genes account for roughly 70 percent of the overall number of cases of the disease.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) Psilocin (4-hydroxy-N,N-dimethyltryptamine) Baeocystin (4-phosphoryloxy-N-methyltryptamine) Norbaeocystin (4-phosphoryloxytryptamine) Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine) The potential psychoactivity of other compounds other than psilocybin and psilocin has been speculated but not confirmed. The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% (wet weight) and 0.37–1.30% (dry weight) in the whole mushroom 0.17–0.78% (wet weight) and 0.44–1.35% (dry weight) in the cap, and 0.09%–0.30% (wet weight) and 0.05–1.27% (dry weight) in the stem, respectively. For quickly and practically measuring the psychoactive contents of most healthy Psilocybe cubensis varieties, it can generally be assumed that there is approximately 15 mg (± 5 mg) of psilocybin per gram of dried mushroom. Furthermore, due to factors such as age and storage method, the psilocybin and psilocin content of a given sample of mushrooms will vary. Individual body composition, brain chemistry and psychological predisposition play a significant role in determining appropriate doses. For a modest psychedelic effect, a minimum of one gram of dried Psilocybe cubensis mushrooms is ingested orally, 0.25–1 gram is usually sufficient to produce a mild effect, 1–2.5 grams usually provides a moderate effect and 2.5 grams and higher usually produces strong effects.
=== Psychological === Early theories of the cause of anorexia linked it to childhood sexual abuse or dysfunctional families; evidence is conflicting, and well-designed research is needed. The fear of food is known as sitiophobia or cibophobia, and is part of the differential diagnosis. Other psychological causes of anorexia include low self-esteem, feeling as if there is lack of control, depression, anxiety, and loneliness. People with anorexia are, in general, highly perfectionistic and most have obsessive compulsive personality traits which may facilitate sticking to a restricted diet. It has been suggested that patients with anorexia are rigid in their thought patterns, and place a high level of importance upon being thin. In the context of anorexia nervosa, this cognitive rigidity refers to the diminished ability to adapt one's behavioral approaches in response to changing circumstances. This weaker cognitive flexibility is a result of neurobiological factors, such as structural differences in prefrontal cortex connectivity, that contribute to the persistence of anorexic behaviors. Although the prevalence rates vary greatly, between 37% and 100%, there appears to be an association between traumatic events and eating disorder diagnosis. Approximately 72% of individuals with anorexia report experiencing a traumatic event prior to the onset of eating disorder symptoms, with binge-purge subtype reporting the highest rates.
Sources: en.wikipedia.org
==== 13 April ==== The United States imposed a naval blockade on Iran on Iran following the failure of the Islamabad Talks to end the war. Iran said it will view the entry of military vessels near the strait as a breach of the ceasefire and will respond accordingly.
Humped animals appear in some cave paintings, which is of interest to paleontologists, who can use such depictions to better understand what extinct fauna looked like. Some cave paintings depict woolly mammoths as being humped, which is corroborated by the humps present on frozen specimens. Similarly, the cave bear is depicted as having a shoulder hump in some French cave paintings. Because of how prominently humps are drawn, it has been theorized that ancient painters used the hump as the starting point when drawing. Humps may not be accurately created in taxidermy. William Temple Hornaday lamented that when stuffing plains bison, there is a tendency to make the hump "a huge, thick, rounded mass like the hump of a dromedary," as opposed to the "high and sharp" muscle hump that bison actually have.
The Kizil Caves complex is the largest of the ancient Buddhist cave sites that are associated with the ancient Tocharian kingdom of Kucha, as well as the largest in Xinjiang. Other famous sites nearby are the Kizilgaha Caves, the Kumtura Caves, Subashi Temple and the Simsim Caves. The Kizil Caves are "the earliest representative grottoes in China". At the time the caves were created, the area of Kucha was following the orthodox Sarvastivadin school of Hinayana Buddhism, although an early and minority Dharmagupta presence has also been noted. The simpler square caves may have been established by the Dharmagupta from the 4th century CE or earlier, while the "central pillar" caves, which flourished from the mid-6th century CE, can rather be associated with the Sarvastivadin school.
Uranium is a chemical element; it has symbol U and atomic number 92. It is a silvery-grey metal in the actinide series of the periodic table. A uranium atom has 92 protons and 92 electrons, of which 6 are valence electrons. Uranium radioactively decays, usually by emitting an alpha particle. The half-life of this decay varies between 159,200 and 4.5 billion years for different isotopes, making them useful for dating the age of the Earth. The most common isotopes in natural uranium are uranium-238 (which has 146 neutrons and accounts for over 99% of uranium on Earth) and uranium-235 (which has 143 neutrons). Uranium has the highest atomic weight of the primordially occurring elements. Its density is about 70% higher than that of lead and slightly lower than that of gold or tungsten. It occurs naturally in low concentrations of a few parts per million in soil, rock and water, and is commercially extracted from uranium-bearing minerals such as uraninite. Many contemporary uses of uranium exploit its unique nuclear properties. Uranium is used in nuclear power plants and nuclear weapons because it is the only naturally occurring element with a fissile isotope – uranium-235 – present in non-trace amounts. However, because of the low abundance of uranium-235 in natural uranium (which is overwhelmingly uranium-238), uranium needs to undergo enrichment so that enough uranium-235 is present. Uranium-238 is fissionable by fast neutrons and is fertile, meaning it can be transmuted to fissile plutonium-239 in a nuclear reactor.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.